Cumberland Pharmaceuticals Reports 2012 Annual Financial Results - Net income increased nearly 100% in fourth quarter. - New Caldolor® pilot study top-line results provide favorable comparison. - International agreements now include Indonesia and India. PR Newswire NASHVILLE, Tenn., Feb. 28, 2013 NASHVILLE, Tenn., Feb. 28, 2013 /PRNewswire/ --Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and annual 2012 financial results. Net Revenue: For the three months ended December 31, 2012, net revenue was $13.7 million, up from $13.0 million in the prior year period. For the year ended December 31, 2012, net revenues were $48.9 million, compared with $51.1 million for 2011. Operating Expenses: Total operating expenses for the three months ended December 31, 2012 were $10.4 million compared to $11.3 million the prior year period. During the fourth quarter of 2012, operating expenses included $0.7 million of non-recurring expenses associated with the realignment of our sales organization. For the year ended December 31, 2012, total operating expenses were approximately $40.0 million compared with $41.3 million for 2011. Net Income: Net income attributable to common shareholders for the three months ended December 31, 2012, was $1.8 million, or $0.09 per diluted share, compared to $0.9 million, or $0.04 per diluted share, for the same period in 2011. This increase resulted from quarter- over-quarter sales growth along with reduced expenses. Net income attributable to common shareholders for the year ended December 31, 2012 increased to $5.8 million, or $0.30 per diluted share, compared to $5.7 million, or $0.28 per diluted share, for 2011. After excluding the one-time sales realignment expenses, adjusted diluted earnings per share were $0.32. ^ (1) Balance Sheet: As of December 31, 2012, Cumberland had $71.0 million in cash and marketable securities, compared to $70.6 million at the end of 2011. Total assets at December 31, 2012, were $98.6 million compared to $95.5 million in 2011. At December 31, 2012, Cumberland had total loans of $4.4 million, down from $4.9 million at the end of 2011. Shareholders' equity increased to $85.7 million at the end of 2012 from $82.9 million for the prior period. "We are pleased with the progress we made in 2012 as highlighted by our financial results, as well as several product milestones, including the expansion of our international presence, the completion of four Caldolor studies, and the allowance of two new Acetadote patents," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "As we move into 2013, we will continue to maximize our near term opportunities while laying the foundation for the long term expansion, diversification and success of our business." Product Highlights Acetadote^® In November 2012, Cumberland received a Notice of Allowance from the United States Patent and Trademark Office for a second patent relating to the new formulation of Acetadote. The new patent will include claims regarding the use of the 200 mg/ml Acetadote formulation to treat patients with acetaminophen overdose and will expire in August 2025. Cumberland also entered into a Settlement Agreement with Paddock Laboratories, LLC and Perrigo Company in November to resolve the challenges and pending litigation between the Company and each of Paddock and Perrigo involving the Acetadote patent. Under the Settlement Agreement, Paddock and Perrigo admit that the Acetadote patent is valid and enforceable and that any Paddock or Perrigo generic Acetadote product (with or without EDTA) would infringe upon the Acetadote patent. In addition, Paddock and Perrigo will not challenge the validity, enforceability, ownership or patentability of the Acetadote patent through its expiration currently scheduled for May 2026. The Company has also entered into a License and Supply Agreement with Paddock and Perrigo. Under the terms of the License and Supply Agreement, if a third party receives final approval from the FDA for an ANDA to sell a generic Acetadote product and such third party has made such generic version available for purchase in commercial quantities in the United States, the Company will supply Perrigo with an authorized generic version of the Company's Acetadote product. In January 2013, Perrigo announced initial distribution of Cumberland's authorized generic acetylcysteine injection product. Caldolor^® Cumberland is pleased to announce new top-line results from a pilot clinical study evaluating the safety and analgesic efficacy of Caldolor (ibuprofen) Injection compared to ketorolac injection in treating pain following knee arthroscopy procedures in adult patients. Fifty-one patients were enrolled at The Ohio State Medical Center. Compared to patients receiving ketorolac, patients receiving intravenous ibuprofen experienced less postoperative pain prior to discharge. Patients receiving Caldolor also needed fewer narcotics and were less likely to require narcotics prior to discharge. This data supports the benefits of using Caldolor in a pre-emptive model of multimodal analgesia. These positive results follow the February release of two recent studies affirming the safety and efficacy of Caldolor in treating pain and fever in adult patients when administered over a shortened infusion time. Top-line results from these two registry studies involved 450 patients who received Caldolor at 34 leading medical centers throughout the United States. The Company continued to expand the international market for Caldolor through strategic partnerships. In December 2012, the application for regulatory approval of Caldolor for fever in Australia by Cumberland's partner Phebra Pty Ltd., was approved. In January 2013, Cumberland entered into agreements with India's Sandor Medicaids Pvt. Ltd. and Indonesia's PT. SOHO Industri Pharmasi (a SOHO Group company) for the commercialization of Caldolor in those countries. Company Update In November 2012, Cumberland completed a realignment of its national sales organization to more efficiently cover key targets in support of all three marketed products, Caldolor, Acetadote and Kristalose, in the United States. Conference Call and Webcast A conference call and live Internet webcast will be held on Thursday, February 28, 2013 at 4:30 p.m. Eastern Time to discuss the Company's fourth quarter 2012 financial results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers). The Conference ID for the rebroadcast is 97366269. The live webcast and rebroadcast can be accessed via Cumberland's website at http://investor.shareholder.com/cpix/events.cfm. About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote^® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor^® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose^® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information, please visit the Company's website at www.cumberlandpharma.com. About Acetadote Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. Serious anaphylactoid reactions, including death in a patient with asthma, have been reported in patients administered acetylcysteine intravenously. Acetadote should be used with caution in patients with asthma or where there is a history of bronchospasm. The total volume administered should be adjusted for patients weighing less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed. If volume is not adjusted, fluid overload can occur, potentially resulting in hyponatremia, seizure and death. For full prescribing information, visit www.acetadote.com. About Caldolor Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever in adults. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticarial, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor. For full prescribing information, including boxed warning, visit www.caldolor.com. About Kristalose Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia and hypernatremia. Nausea and vomiting have been reported. Use with caution in diabetics. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing information, visit www.kristalose.com. Forward-Looking Statements This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's most recent Form 10-K and subsequent 10-Q's as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (unaudited) December 31, 2012 and 2011 2012 2011 ASSETS Current assets: Cash and cash equivalents $ 54,349,381 $ 70,599,146 Marketable securities 16,686,136 — Accounts receivable, net of allowances 6,017,201 7,082,890 Inventories 6,218,355 5,774,694 Prepaid and other current assets 1,671,091 1,627,455 Deferred tax assets 2,290,078 2,223,882 Total current assets 87,232,242 87,308,067 Property and equipment, net 1,188,914 1,119,339 Intangible assets, net 9,476,798 7,023,064 Deferred tax assets 50,411 — Other assets 645,366 67,846 Total assets $ 98,593,731 $ 95,518,316 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 2,790,554 $ 1,513,548 Accrued liabilities 5,264,806 5,086,400 Total current liabilities 8,055,360 6,599,948 Revolving line of credit 4,359,951 4,859,951 Deferred tax liability — 645,029 Other long-term liabilities 611,933 578,119 Total liabilities 13,027,244 12,683,047 Commitments and contingencies Equity: Shareholders' equity: Common stock – no par value; 100,000,000 shares authorized; 18,937,107 and 20,020,535 shares 67,197,167 70,272,155 issued and outstanding as of December31, 2012 and 2011, respectively Retained earnings 18,499,154 12,656,662 Total shareholders' equity 85,696,321 82,928,817 Noncontrolling interests (129,834) (93,548) Total equity 85,566,487 82,835,269 Total liabilities and equity $ 98,593,731 $ 95,518,316 CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Condensed Consolidated Statements of Income (unaudited) Three months ended Years ended December 31, December 31, 2012 2011 2012 2011 Revenues: Net product $ 13,637,333 $ 12,782,848 $ 47,944,031 $ 50,893,794 revenue Other revenue 59,033 248,982 907,206 248,982 Net revenues 13,696,366 13,031,830 48,851,237 51,142,776 Costs and expenses: Cost of products 2,172,762 1,951,200 5,046,179 5,362,554 sold Selling and 4,942,425 4,686,486 20,329,493 20,940,060 marketing Research and 441,215 1,758,326 5,095,172 5,028,072 development General and 2,765,056 2,784,427 9,096,165 9,307,301 administrative Amortization 121,915 140,122 466,126 655,302 Total costs and 10,443,373 11,320,561 40,033,135 41,293,289 expenses Operating income 3,252,993 1,711,269 8,818,102 9,849,487 Interest income 48,791 63,099 304,865 210,727 Interest expense (15,616) (24,460) (71,985) (353,497) Income before 3,286,168 1,749,908 9,050,982 9,706,717 income taxes Income tax expense (1,492,213) (841,783) (3,244,776) (4,080,204) Net income 1,793,955 908,125 5,806,206 5,626,513 Net loss at subsidiary attributable to 11,545 3,540 36,286 31,343 noncontrolling interests Net income attributable to $ 1,805,500 $ 911,665 $ 5,842,492 $ 5,657,856 common shareholders Earnings per share attributable to common shareholders: Basic $ 0.09 $ 0.05 $ 0.30 $ 0.28 Diluted $ 0.09 $ 0.04 $ 0.30 $ 0.28 Weighted-average shares outstanding: Basic 19,048,945 20,130,211 19,564,625 20,342,913 Diluted 19,245,047 20,318,176 19,787,537 20,572,132 CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows (unaudited) Years ended December 31, 2012 and 2011 2012 2011 Cash flows from operating activities: Net income $ 5,806,206 $ 5,626,513 Adjustments to reconcile net income to net cash flows provided by operating activities: Depreciation and amortization expense 901,649 1,040,407 Deferred tax expense (benefit) (829,846) 1,665,110 Share-based compensation 636,528 779,305 Excess tax benefit derived from exercise of (3,760,766) (2,355,345) stock options Noncash interest expense 24,075 137,487 Noncash investment gains (45,814) — Net changes in assets and liabilities affecting operating activities: Accounts receivable 1,065,689 (1,937,396) Inventory (443,661) 1,909,148 Prepaid, other current assets and other assets (648,941) (399,393) Accounts payable and other accrued liabilities 4,373,276 2,296,535 Other long-term liabilities 56,787 (40,224) Net cash provided by operating activities 7,135,182 8,722,147 Cash flows from investing activities: Additions to property and equipment (464,893) (257,502) Additions to intangibles (2,071,926) (180,269) Proceeds from sale of marketable securities 5,220,480 — Purchases of marketable securities (21,860,802) — Net cash used in investing activities (19,177,141) (437,771) Cash flows from financing activities: Net borrowings (repayments) on line of credit (500,000) 3,034,000 Principal payments on note payable — (5,333,333) Payments made in connection with repurchase of (8,086,594) (4,247,440) common shares Costs of financing for long-term debt and — (17,637) credit facility Proceeds from exercise of stock options 618,022 629,865 Excess tax benefit derived from exercise of 3,760,766 2,355,345 stock options Net cash used in financing activities (4,207,806) (3,579,200) Net increase (decrease) in cash and cash (16,249,765) 4,705,176 equivalents Cash and cash equivalents, beginning of year 70,599,146 65,893,970 Cash and cash equivalents, end of year $ 54,349,381 $ 70,599,146 CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Reconciliation of Net Income Attributable to Common Shareholders to Adjusted Net Income Attributable to Common Shareholders and Adjusted Earnings Per Share Attributable to Common Shareholders: (unaudited) Three months ended Years ended December 31, December 31, 2012 2011 2012 2011 Net income attributable $ 1,805,500 $ 911,665 $ 5,842,492 $ 5,657,856 to common shareholders Costs associated with sales force 685,267 — 685,267 — realignment** Income tax effect of sales force realignment (277,533) — (277,533) — costs Net costs of sales 407,734 — 407,734 — force realignment Adjusted net income attributable to common $ 2,213,234 $ 911,665 $ 6,250,226 $ 5,657,856 shareholders Adjusted earnings per share attributable to common shareholders: Basic $ 0.12 $ 0.05 $ 0.32 $ 0.28 Diluted $ 0.12 $ 0.04 $ 0.32 $ 0.28 Weighted-average shares outstanding: Basic 19,048,945 20,130,211 19,564,625 20,342,913 Diluted 19,245,047 20,318,176 19,787,537 20,572,132 ** On November 29, 2012, Cumberland Pharmaceuticals Inc. (the "Company") implemented a realignment of its national sales organization to more efficiently cover key targets in support of its three marketed products, Caldolor, Acetadote and Kristalose . As a result of this realignment the Company's sales personnel totaling 64 individuals, consolidated into 8 nationwide districts. The Company does not expect to have further changes to its sales personnel as a result of the realignment. The costs associated with the sales force realignment are one-time expenses recorded during the fourth quarter ending December 31, 2012. As management believes these costs are nonrecurring and important to understanding the Company's business operations, it has presented these separately. The Company provided the above adjusted financial performance measures, which are considered "non-GAAP" financial measures under applicable Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with generally accepted accounting principles. The definition of these non-GAAP measures may differ from similarly titled measures used by others. Management believes these non-GAAP financial performance measures are important as they eliminate nonrecurring sales realignment costs. The Company used these non-GAAP financial measures to facilitate management's internal comparisons of the Company's operating results, as well as to reconcile to guidance provided to investors. In addition, the use of non-GAAP financial measures provides greater transparency to investors of supplemental information used by management in its financial and operational decision-making, including the evaluation of the Company's operating performance. The Company defines these non-GAAP financial measures as follows: oAdjusted net income attributable to common shareholders: net income attributable to common shareholders adjusted for the one-time expenses associated with the sales force realignment during the fourth quarter ending December 31, 2012, net of related income tax effect. oAdjusted basic earnings per share: adjusted net income attributable to common shareholders divided by basic weighted-average shares outstanding. oAdjusted diluted earnings per share: adjusted net income attributable to common shareholders divided by diluted weighted-average shares outstanding. SOURCE Cumberland Pharmaceuticals Inc. Website: http://www.cumberlandpharma.com Contact: Investor Contact, Elizabeth Davis, Corporate Relations, +1-615-255-0068, email@example.com; or Media Contact, Rebecca Kirkham, Lovell Communications, +1-615-297-7766, firstname.lastname@example.org
Cumberland Pharmaceuticals Reports 2012 Annual Financial Results
Press spacebar to pause and continue. Press esc to stop.